Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cronos Group Inc.TSX: CRON.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was $0, compared with $801.21K a year earlier. Trailing-twelve-month research & development was $3.68M. Over 3 fiscal years it compounded at -30.1% a year.

Context

  • Research & development amounted to 3.0% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $919.26K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$4.53M+7.1% YoY
LTMMar 2026
$3.68M-8.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+7.1%——
3-year CAGR-30.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
4.53M USD
Year-over-year change
+7.1%
4-year CAGR
-32.4%

Research & Development vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.7% is the 2nd highest of 4, against a peer median of -61.8%.
  • Research & development amounts to 2.3% of revenue for CRON.TO, versus a peer median of 0.0%.
CRON.TO Competitors
Research & Development for CRON.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$33.61M CAD+45.4%+25.2%6.6%
CRON.TOCronos Group Inc.LTM Mar 2026$3.68M USD-8.7%-30.1%2.3%
TLRY.TOTilray Brands, Inc.LTM Feb 2026$246.09K USD-61.8%-42.8%0.0%
EXE.TOExtendicare Inc.LTM Jun 2026CA$0 CAD——0.0%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$0 CAD——0.0%
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$0 CAD-100.0%—0.0%
Peer median (excluding CRON.TO) —-61.8%-8.8%0.0%

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.02M87.54M87.03M117.5M149.15M
Cost of Revenue81.47M71.96M75.15M87.05M87.45M
Gross Profit(17.45M)15.58M11.88M30.45M61.7M
Gross Margin-27.3%17.8%13.7%25.9%41.4%
Research & Development21.66M13.25M5.83M4.22M4.53M
Selling, General & Admin120.67M101.64M80.74M76.74M75.01M
Operating Expenses272.09M128.01M96.48M106.91M79.54M
Depreciation & Amortization13.36M11.52M7.44M8.84M14.48M
EBITDA(150.79M)(93.81M)(72.28M)(45.37M)(2.94M)
EBITDA Margin-235.5%-107.2%-83.0%-38.6%-2.0%
Operating Income(289.54M)(112.44M)(84.6M)(76.46M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income8.92M21.84M52.07M49.52M40.66M
Interest Expense00000
Other Income / Expenses162.1M(9.66M)11.1M113.01M419.21K
Income Before Tax(127.44M)(122.1M)(73.49M)36.55M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(427.41K)34.48M(3.23M)(3.44M)(14.44M)
Net Income(392.81M)(170.26M)(73.79M)41.04M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(0.34)(0.42)(0.18)0.10(0.03)
EPS (Diluted)(0.34)(0.42)(0.18)0.10(0.03)
Weighted Avg Shares369.73M370.39M380.96M382.16M383.47M
Weighted Avg Shares (Diluted)370.39M370.39M380.96M382.16M383.47M

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.